HFpEF in Japan: When an Epidemiological Transition Becomes an Epidemiological Opportunity.

No abstract is available for this paper.

• Publication year

  2023

• Venue

  Journal of Cardiac Failure

• Publication date

  2023-02-21

• Fields of study

  Medicine, Environmental Science

• Identifiers
  DOI 10.1016/j.cardfail.2023.02.005PMID 36925045
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Epidemiology, Pathophysiology, Diagnosis, and Therapy of Heart Failure With Preserved Ejection Fraction in Japan.

  2023cited by this paper
• SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials.

  2022cited by this paper
• Empagliflozin in Patients with Chronic Kidney Disease

  2022cited by this paper
• Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.

  2019cited by this paper
• Spironolactone for heart failure with preserved ejection fraction.

  2014cited by this paper
• Spironolactone for heart failure with preserved ejection fraction.

  2014cited by this paper

• No citing papers are available for this paper.